Copay help by condition · Heart and circulation · read 2026-11-10
Heart failure (HF): which charitable copay funds are open
1 fund for Heart failure says it is open right now, of the 3 we hold (read 2026-11-10).
Open: Heart failure (HF) health equity from TotalAssist (Patient Advocate Foundation copay funds). Eligibility is each fund's own rule.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Heart failure
- OpenHeart failure (HF) health equity
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $2,500Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Open. Source page
- WaitlistHeart Failure
Accessia Health ·
Award level: not statedInsurance supported: not stated
The program page lists the program as At Capacity, Waitlist Open. Its tracks: privately insured track waitlist open (at capacity); publicly insured track waitlist open (at capacity). It shows no date. Source page
- Closed or at capacityHeart failure (HF)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $2,500Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Heart failure
5 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 4 have a program (in our assistance finder or on the program's own page) and 2 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Farxiga Dapagliflozin Every route for this drug | To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10 | Farxiga Savings (via AstraZeneca) Heart Medication Assistance (Multiple Programs) Diabetes Medication Assistance (Multiple Programs) AZ&Me Prescription Savings Program Not in its current list The program's page printed this drug in an earlier list and not in its current one. | $183.33 for a 30-day supply, effective 2027-01-01 |
| Jardiance Empagliflozin Every route for this drug | ... to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10 | Jardiance Savings (via Boehringer Ingelheim/Lilly) Heart Medication Assistance (Multiple Programs) Diabetes Medication Assistance (Multiple Programs) and 1 more | $202.33 for a 30-day supply, effective 2027-01-01 |
| Synjardy XR, Synjardy Empagliflozin/Metformin Hcl Every route for this drug | CV death and hospitalization for heart failure in adults with heart failure. Label on openFDA, read 2026-11-10 | Boehringer Ingelheim Cares Foundation Limited | not in the CMS negotiated-price file |
| Kerendia Finerenone Every route for this drug | ... cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%. Label on openFDA, read 2026-11-10 | Bayer US Patient Assistance Foundation (program page) | not in the CMS negotiated-price file |
| Amvuttra Vutrisiran Sodium | ... the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Related conditions
Group: Heart and circulation. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-10. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: heart-failure.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Heart failure?
As read on 2026-11-10, 1 of the 3 funds we hold for Heart failure say they are open: Heart failure (HF) health equity from TotalAssist (Patient Advocate Foundation copay funds). Funds open and close, so check the source page before you apply.
Which organizations run funds for Heart failure?
TotalAssist (Patient Advocate Foundation copay funds) and Accessia Health. Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-10). We do not promise a fund is still in that state today.